Log in to save to my catalogue

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T reg cells

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T reg cells

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_38418879

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T reg cells

Publication information

Publisher

England

More information

Scope and Contents

Contents

Tiragolumab, an anti-TIGIT antibody with an active IgG1κ Fc, demonstrated improved outcomes in the phase 2 CITYSCAPE trial (ClinicalTrials.gov: NCT03563716 ) when combined with atezolizumab (anti-PD-L1) versus atezolizumab alone
. However, there remains little consensus on the mechanism(s) of response with this combination
. Here we find that...

Alternative Titles

Full title

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and T reg cells

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmed_primary_38418879

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_38418879

Other Identifiers

E-ISSN

1476-4687

DOI

10.1038/s41586-024-07121-9

How to access this item